En Es
Categories

Industry News

Pluslife and FIND Set Collaborate to Empower LMICs with Next-Gen POC Molecular Testing in Women’s Healthcare

By Labmedica International staff writers
19 Sep 2022

Image: The collaboration will provide affordable POC MDx platforms for LMICs to increase women’s accessibility to diagnostics (Photo courtesy of Pluslife)

Guangzhou Pluslife Biotechnology (Pluslife, Guangzhou, China) and the Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) have entered into a strategic collaboration to support low- and middle-income countries (LMICs) in the development of diagnostic tools for women’s healthcare by providing access to next generation point of care (POC) molecular testing technology.


The COVID-19 pandemic has posed huge challenges to global public health and welfare, especially in LMICs. FIND, the global alliance for diagnostics that seeks to ensure equitable access to reliable diagnosis around the world, has realized that POC molecular diagnostic (MDx) platforms with multiple target detection play a significant role in earlier detection of SARS-CoV-2 infection and reducing its transmission. However, the centralized format and high prices of current MDx platforms have led to inadequate diagnostic capabilities. Hence, decentralized and affordable POC MDx platforms can enable more effective control of SARS-CoV-2 and other infections, such as HIV/HCV/HBV/HPV, and other bacterial infections.


One of the most significant characteristics of Pluslife’s next-generation POC molecular diagnostics is a multi-scenario application, which enables the decentralization of MDx in LMICs. During pandemics and periods high prevalence of infectious diseases, MDx platforms under a centralized format are often overloaded with samples due to extremely high testing volumes. The Pluslife next generation POC molecular system can ease the burden on the entire health system by allowing tests to be conducted with a fast set-up time and without any constraints. Through the collaboration with FIND, Pluslife Biotech plans to make valuable contributions to foster the adoption of a decentralized POC platform by LMICs with a focus on affordability and reliability.


The collaboration between Pluslife and FIND aims to strengthen the MDx platforms in LMICs by providing affordable POC MDx platforms to increase accessibility to essential diagnostics and tests for women. Currently, only 1% of primary healthcare facilities have access to essential diagnostics, and some tests that are specifically required for women are not available to all women in LMICs. Applying the Pluslife POC molecular system in such resource-limited settings can increase the testing capability in primary healthcare facilities in an efficient and economic manner and rapidly expand its usage to lower-level medical facilities such as clinics and test centers. Pluslife will remain dedicated to its collaboration with FIND, and both parties will together make diagnosis more accessible to improve the living standards of the people in LMICs.


“The COVID-19 pandemic has accelerated the advancement of technologies that have the potential to make a huge impact. Point-of-care molecular testing, with the capacity to test for multiple diseases, can help us change the question from ‘is this COVID?’ to ‘what is this?’, in primary care clinics where most people first seek care,” said Dr. Marta Fernández Suárez, Chief Technology Officer at FIND. “We are pleased to be partnering with Pluslife to explore the potential of their promising technology as part of our mission to realize diagnosis for all.”


“Pluslife and FIND shared the same goal to spur diagnostic innovation and make diagnostic more accessible to LMICs, it is truly a significant social responsibility for Pluslife to honor,” commented Pluslife CEO Noah Chen, “Pluslife Next-Generation POC molecular system will be launched as a reform of LMICs health system, to improve the efficiency of testing and the resilience of the different health channels, and finally achieves more accessible and affordable test for all.”


Related Links:
Pluslife 
FIND 



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

23 Nov 2022
Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures
The increasing demand for visualization systems for complex surgical procedures, growing demand for minimally invasive surgeries, and rising prevalence of chronic diseases are expected to help the global visualization instruments for minimally invasive surgery (MIS) market register a CAGR of 7.2% between 2022 and 2031 and reach a value of USD 21 billion by 2031.
Read More
11 Nov 2022
Global Diagnostic ECG Market Driven by Increased Incidence of Cardiac Diseases
The rising prevalence of such chronic conditions is necessitating the need for diagnosis and treatment in order to keep track of the patient's daily medical condition and maintain medical records. This, coupled with rising hospitalization of the older population for the treatment of cardiac diseases, has increased the need for electrocardiograph (ECG) diagnosis.
Read More
11 Nov 2022
Radcal to Supply Quality Assurance X-Ray Testing Equipment to West Physics
Radcal Corporation (Monrovia, CA, USA), a leading manufacturer of diagnostic X-ray quality assurance (QA) meters, has reached an agreement with West Physics (Atlanta, GA, USA), one of the largest and most successful Medical Physics groups in the U.S., to supply QA X-ray testing equipment.
Read More
09 Nov 2022
Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling
Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.
Read More
08 Nov 2022
Global Infusion Pumps Market Driven by Increasing Incidence of Chronic Diseases
Rising demand for ambulatory infusion pumps in home care, increasing incidence of chronic diseases along with a rapid growth of the geriatric population, and growing number of surgical procedures being performed, are driving the growth of the global infusion pumps market. As a result, the market is projected to register a CAGR of 7% from USD 14.7 billion in 2022 to USD 20.5 billion by 2027.
Read More
07 Nov 2022
Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System
Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nan?mix eLab system in the UK, Germany, France, Ireland and South Africa.
Read More
07 Nov 2022
AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests
An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
Read More
01 Nov 2022
Global Infectious Respiratory Disease Diagnostics Market Driven by New Multiplex PCR Tests and POC Products
The global infectious respiratory disease diagnostics market size is expected to reach USD 43.6 billion by 2030, driven by an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & non-profit organizations to introduce novel & innovative products to address the growing demand.
Read More
01 Nov 2022
Johnson & Johnson to Acquire Cardiovascular Technology Company Abiomed in USD 16.6 Billion Deal
Johnson & Johnson (New Brunswick, N.J., USA) has entered into a definitive agreement to acquire all outstanding shares of Abiomed, Inc. (Danvers, MA, USA) in a deal valued at approximately USD 16.6 billion which includes cash acquired.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions